KCT0001583招募中未知
A Phase II trial of preoperative HER2 targeting and endocrine therapy in postmenopausal women with HER2 and HR positive breast cancer
Yonsei University Health System, Gangnam Severance Hospital0 个研究点目标入组 132 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 132
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 o Limit(—)
- 性别
- Female
入选标准
- •1) Patients must have histological confirmation that the patient has operable invasive breast cancer.
- •2) Measurable lesions = 1cm
- •3) Age = 20 years
- •4) ECOG performance status: 0 or 1
- •5) Postmenopausal women
- •Definition of postmenopausal
- •Age = 55 years and no history of menstruation or
- •Age < 55 years: no history of menstruation within the last 12 months and FSH(Follicle stimulating Hormone) = 30 mlU/mL
- •6) HER2(Human Epidermal Growth factor Receptor 2) Positive
- •IHC(Immunohistochemistry) Score is 3+ or if IHC Score is 2+, (must have positive with FISH(Fluorescence in situ hybridization)/SISH(Silver enhanced in situ hybridization) tests)
- •7) ER(Estrogen Receptor) Positive
- •Allred score = 3/8 or Modified Allred score = 4/7
- •8) Adequate organ and bone marrow function:
- •WBC(White Blood Cell) =2.5x10^9/L
- •ANC(Absolute Neutrophil Count) =1.5x10^9/L
- •Platelet =100x10^9/L
- •Hemoglobin =10g/dl
- •Serum creatinine =1.5mg/dl
- •AST(Aspartate aminotransgerase) and ALT(Alanine aminotransferase) =2 x ULN(Upper limit of normal)
- •Alkaline phosphatase =2.5 x ULN
- •Total bilirubin =1.5mg/dl
- •9) Adequate Cardiac Function
- •Normal ECG(Electrocardiogram) results
- •(not Consider clinically non-significant arrythmia and ischemic change as normal)
- •MUGA(Multi Gated Blood Pool Scan) or Echo(Echocardiography) shows LVEF(Left Ventricular ejection fraction) =55%
- •10) Ability to understand a written informed consent form, and the willingness to sign it.
排除标准
- •1) Inflammatory breast cancer
- •2) Bilateral breast cancer
- •3) Previous surgical history of breast cancer (excluding biopsy for diagnostic purposes)
- •4) History of treatment for breast cancer
- •(Including hormone therapy, chemotherapy, and radiation therapy)
- •5) History of treatment for malignant tumor other than breast cancer within last five years.
- •(Excluding treated non-melanoma skin cancer and localized cervical cancer and no evidence of recurrence of thyroid cancer for 5 years after surgery)
- •6) Within the last six months, if the patients have any history below:
- •- Myocardial Infarction
- •- Uncontrolled or moderate cardiovascular diseases
- •- Heart failure (New York Heart Association(NYHA) Class II)
- •- Uncontrolled angina
- •- Clinically significant epicardial disease
- •- History of cardiac amyloidosis
- •7) Presence of any severe medical condition that, in the opinion of the investigator, would limit the patients successful participation.
- •8) Subjects who have enrolled other study and received treatment from other study within the last 4 weeks of starting of this study.
研究者
相似试验
尚未招募
不适用
Efficacy analysis of anti-HER2 treatment in HER2-enriched early breast cancer identified by PAM50KCT0006154Yonsei University Health System, Gangnam Severance Hospital59
招募中
1 期
Phase I clinical study on the safety of HER2-specific chimeric antigen receptor (CAR) gene-modified T cell therapyHER2 positive osteosarcoma/soft tissue sarcoma and gynecologic malignancyJPRN-jRCT2033220088Yozo Nakazawa12
进行中(未招募)
1 期
PREDIX HER2 - preoperative treatment of HER2 positive breast cancerPrimary breast cancerMedDRA version: 20.0Level: PTClassification code: 10006201Term: Breast cancer stage III Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10006188Term: Breast cancer female NOS Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10006200Term: Breast cancer stage II Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10006191Term: Breast cancer male NOS Class: 10029104CTIS2023-508411-23-00Karolinska University Hospital200
进行中(未招募)
1 期
PREDIX HER2 - preoperative treatment of HER2 positive breast cancerEUCTR2014-000808-10-SEKarolinska University Hospital200
进行中(未招募)
1 期
DetectIV - Treatment of patients with advanced metastatic breast cancer and circulating blood cells devoid of Her2/neu.EUCTR2013-001269-18-DEniversitätsklinikum Ulm (AöR)300
